HARMONY BIOSCIENCES HLDG INC (HRMY)

Sector: Health Care

    Home/Companies/HRMY/Annual Meeting

2026 Annual Meeting Analysis

HARMONY BIOSCIENCES HLDG INC · Meeting: May 14, 2026

Policy v1.2high confidenceView Filing ↗
For informational purposes only. This AI-generated analysis applies a published voting policy to publicly available proxy filings. It does not constitute investment advice, proxy voting advice, or a solicitation of any kind. AI analysis may be incomplete or inaccurate — always review the actual filing and make your own independent decision.

Directors FOR

3

Directors AGAINST

1

Say on Pay

AGAINST

Auditor

FOR

Director Elections

Election of Four Class III Directors to Serve Until the 2029 Annual Meeting

3 FOR/1 AGAINST

Against Analysis

✗ AGAINST
Andreas Wicki, Ph.D.TSR underperformance vs peer groupdirector since 2017 full tenure overlap

Dr. Wicki has served since 2017, giving him full overlap with the 3-year underperformance period during which HRMY's stock fell 14.3% while the company-disclosed peer group median rose 46.6% — a gap of 60.9 percentage points, far exceeding the 20-point threshold that applies when absolute 3-year returns are negative; the 5-year gap of 77.5 percentage points also exceeds the 20-point threshold for negative absolute returns, confirming this is not a short-term blip, so the 5-year mitigant does not apply.

For Analysis

✓ FOR
Geno Germano

Mr. Germano is a new nominee and is not yet a sitting director, so the TSR trigger does not apply; he brings over 30 years of pharmaceutical industry experience including senior leadership at Pfizer, and his appointment fills a vacancy created by a departing director.

✓ FOR
Troy Ignelzi

Mr. Ignelzi joined the board in April 2026, which is within the 24-month new-director exemption period, so the TSR trigger does not apply; he has relevant financial expertise as a seasoned CFO at multiple biotech companies.

✓ FOR
Ron Philip

Mr. Philip joined the board in April 2025, which is within the 24-month new-director exemption period, so the TSR trigger does not apply; he brings relevant life sciences leadership experience including CEO roles at Spark Therapeutics and Orbital Therapeutics.

Of the four Class III nominees, one (Dr. Wicki, director since 2017) triggers an AGAINST vote due to sustained and severe stock underperformance relative to the company's own peer group — HRMY lost 14.3% over 3 years while peers gained 46.6% on median, a 60.9-percentage-point gap well above the 20-point policy threshold, with the 5-year record confirming no mitigant applies. The three other nominees (Germano, Ignelzi, Philip) are either new or within the 24-month exemption window and receive FOR votes.

Say on Pay

✗ AGAINST

CEO

Jeffrey M. Dayno, M.D.

Total Comp

$7,899,535

Prior Support

97.6%%

variable pay above benchmark with TSR underperformancepay for performance misalignment

CEO Jeffrey Dayno received total compensation of approximately $7.9 million in 2025, driven largely by equity awards totaling $6.6 million in reported value — a significant increase from $5.5 million in equity in 2024 — while HRMY's stock declined 14.3% over three years compared to a 46.6% median gain for the company's own disclosed peer group, a gap of 60.9 percentage points. Under the pay-for-performance alignment check, variable and equity pay is above benchmark while total shareholder return materially underperforms sector peers by more than 20 percentage points over three years, which is the condition that triggers a No vote on incentive compensation. Although the prior say-on-pay vote was 97.6% supportive (well above the 70% threshold), the structural misalignment between above-benchmark equity grants and severe multi-year stock underperformance relative to peers fails the pay-for-performance test under policy.

Auditor Ratification

✓ FOR

Auditor

Deloitte & Touche LLP

Tenure

9 yrs

Audit Fees

$1,587,000

Non-Audit Fees

$693,000

Deloitte has served since 2017 (approximately 9 years), well below the 25-year tenure threshold; the non-audit fee ratio is 43.7% (tax fees of $693,000 divided by audit fees of $1,587,000), which is below the 50% threshold that would raise independence concerns; and Deloitte is a Big 4 firm appropriate for a $1.6 billion market cap company.

Overall Assessment

The 2026 Harmony Biosciences annual meeting presents three proposals: director elections, auditor ratification, and say-on-pay. HRMY's stock has significantly underperformed its own disclosed compensation peers over the past three years (down 14.3% vs. peer median up 46.6%), which drives AGAINST votes for the longest-tenured director nominee (Dr. Wicki) and for the say-on-pay proposal due to above-benchmark executive equity grants not being justified by shareholder returns; the auditor ratification passes all policy screens and receives a FOR vote.

Filing date: April 3, 2026·Policy v1.2·high confidence

Compensation Peer Group

13 companies disclosed in 2026 proxy filing

ACADAcadia Pharmaceuticals
ALKSAlkermes
AVDLAvadel Pharmaceuticals
AXSMAxsome Therapeutics
CPRXCatalyst Biosciences
ITCIIntra-Cellular Therapies
IONSIonis Pharmaceuticals
JAZZJazz Pharmaceuticals
MRNSMarinus Pharmaceuticals
NBIXNeurocrine Biosciences
PTCTPTC Therapeutics
SAGESage Therapeutics
SUPNSupernus Pharmaceuticals